News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CMS (00867.HK) Showcases Self-Developed INHBE Small Nucleic Acid Drug CMS-D008 at ADA Conference
CMS (00867.HK) announced that the preclinical results of its self-developed innovative drug, the INHBE small nucleic acid therapy CMS-D008 injection ("CMS-D008"), were presented in...
Reset
Send
The window will close in 5 seconds
CMS (00867.HK) Showcases Self-Developed INHBE Small Nucleic Acid Drug CMS-D008 at ADA Conference
Close
Recommend
2
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CMS (00867.HK)  -0.050 (-0.460%)    Short selling $11.23M; Ratio 32.042%   announced that the preclinical results of its self-developed innovative drug, the INHBE small nucleic acid therapy CMS-D008 injection ("CMS-D008"), were presented in a poster session at the 86th American Diabetes Association (ADA) Scientific Sessions. As the largest and most authoritative annual academic event in the global diabetes and metabolic disease field, the ADA conference gathered more than 12,000 leading clinical experts, research scholars and frontline healthcare professionals from around the world to discuss and witness cutting-edge diagnostic and therapeutic achievements as well as technological breakthroughs.

CMS-D008 demonstrated encouraging non-clinical data. The preclinical results presented at the ADA conference showed that, in obese animal models, CMS-D008 effectively and sustainably inhibited INHBE expression, achieving significant weight and fat reduction without affecting muscle mass, while maintaining a favorable safety profile. The therapy is expected to enable healthy weight loss. (su/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-11 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.